Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology
May 22nd 2022
By Skylar JeremiasVideo
The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.